We are live on !
Find out more
SC
Stempoint Capital Portfolio holdings
AUM
$581M
Turnover
56.9%
1-Year Est. Return
373.68%
This Fund
S&P 500
This Quarter Est. Return
+35.11%
1 Year Est. Return
+373.68%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$581M
AUM Growth
+$58.2M
(+11%)
Cap. Flow
-$54.7M
Cap. Flow % of AUM
Cap. Flow %
-9.43%
Top 10 Holdings %
Top 10 Hldgs %
40.99%
Holding
116
New
34
Increased
19
Reduced
30
Closed
32
Avg Time Held
Equity + Options
0.4
years
Top 10 Avg Time Held
Equity + Options
0.1
years
Top 20 Avg Time Held
Equity + Options
0.5
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.1
years
Top 20 Avg Time Held Equity only
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tango Therapeutics
TNGX
|
+$25.3M |
| 2 |
Erasca
ERAS
|
+$19M |
| 3 |
Tyra Biosciences
TYRA
|
+$14.5M |
| 4 |
First Tracks Biotherapeutics
TRAX
|
+$11.6M |
| 5 |
Kiniksa Pharmaceuticals
KNSA
|
+$10.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scholar Rock
SRRK
|
+$38.5M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
+$28.4M |
| 3 |
Revolution Medicines
RVMD
|
+$17.8M |
| 4 |
MBX Biosciences
MBX
|
+$14.9M |
| 5 |
Immunovant
IMVT
|
+$14.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.23% |
| 2 | Miscellaneous | 0.45% |
| 3 | Financials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
InflaRx
IFRX
$214M
| $7.23M | 1.25% |
+3,228,255
| New | +$6.07M |
2026 Q2
0 quarters
|
|
27
Amylyx Pharmaceuticals
AMLX
$3.43B
| $6.9M | 1.19% |
384,304
-285,381
| -43% | -$4.41M |
2025 Q3
3 quarters
|
|
28
Celldex Therapeutics
CLDX
$2.33B
| $6.64M | 1.14% |
178,412
-75,855
| -30% | -$2.45M |
2026 Q1
1 quarter
|
|
29
Ovid Therapeutics
OVID
$424M
| $6.5M | 1.12% |
+2,417,283
| New | +$6.24M |
2026 Q2
0 quarters
|
|
30
Equillium
EQ
$78.6M
| $6.45M | 1.11% |
+2,016,607
| New | +$4.83M |
2026 Q2
0 quarters
|
|
31
Definium Therapeutics
DFTX
$4.43B
| $6.45M | 1.11% |
137,124
-188,359
| -58% | -$4.65M |
2026 Q1
1 quarter
|
|
32
Cytokinetics
CYTK
$8.71B
| $6.44M | 1.11% |
75,603
-53,974
| -42% | -$3.88M |
2025 Q4
2 quarters
|
|
|
DMRA
33
Damora Therapeutics
DMRA
$1.19B
| $5.62M | 0.97% |
+216,194
| New | +$5.24M |
2026 Q2
0 quarters
|
|
34
Inventiva
IVA
$704M
| $5.39M | 0.93% |
+1,426,320
| New | +$6.85M |
2026 Q2
0 quarters
|
|
35
Century Therapeutics
IPSC
$266M
| $5.26M | 0.91% |
+2,146,182
| New | +$4.9M |
2026 Q2
0 quarters
|
|
36
Aura Biosciences
AURA
$652M
| $5.07M | 0.87% |
+714,280
| New | +$5.11M |
2026 Q2
0 quarters
|
|
37
EyePoint Inc
EYPT
$37.9M
| $4.84M | 0.83% |
338,471
-472,293
| -58% | -$6.32M |
2025 Q4
2 quarters
|
|
38
Assembly Biosciences
ASMB
$410M
| $4.68M | 0.81% |
170,378
-15,057
| -8% | -$410K |
2025 Q3
3 quarters
|
|
39
Whitehawk Therapeutics
WHWK
$172M
| $4.68M | 0.81% |
1,021,037
+81,668
| +9% | +$340K |
2025 Q3
3 quarters
|
|
40
Xenon Pharmaceuticals
XENE
$3.4B
| $4.59M | 0.79% |
76,075
-64,680
| -46% | -$3.59M |
2025 Q3
3 quarters
|
|
41
uniQure
QURE
$1.54B
| $4.06M | 0.7% |
88,115
+10,049
| +13% | +$263K |
2024 Q4
6 quarters
|
|
42
Compass Pathways
CMPS
$1.54B
| $4.03M | 0.69% |
+284,769
| New | +$2.89M |
2026 Q2
0 quarters
|
|
43
Avalyn Pharma
AVLN
$1.03B
| $3.88M | 0.67% |
+118,000
| New | +$3.41M |
2026 Q2
0 quarters
|
|
44
MapLight Therapeutics
MPLT
$445M
| $3.83M | 0.66% |
106,906
+6,906
| +7% | +$199K |
2025 Q4
2 quarters
|
|
45
Alumis Inc
ALMS
$821M
| $3.82M | 0.66% |
135,736
-93,830
| -41% | -$2.18M |
2026 Q1
1 quarter
|
|
46
Axsome Therapeutics
AXSM
$8.16B
| $3.76M | 0.65% |
+15,375
| New | +$3.33M |
2026 Q2
0 quarters
|
|
47
Monte Rosa Therapeutics
GLUE
$909M
| $3.72M | 0.64% |
+153,544
| New | +$2.9M |
2026 Q2
0 quarters
|
|
48
Acadia Pharmaceuticals
ACAD
$3.41B
| $3.62M | 0.62% |
143,167
-99,399
| -41% | -$2.19M |
2026 Q1
1 quarter
|
|
49
Solid Biosciences
SLDB
$635M
| $3.58M | 0.62% |
358,780
+163,377
| +84% | +$1.24M |
2026 Q1
1 quarter
|
|
50
Personalis
PSNL
$1.7B
| $3.32M | 0.57% |
+247,783
| New | +$2.02M |
2026 Q2
0 quarters
|
|
Similar funds
PM
RIS
GFI
CCWM
MFS
MIP
CA
LCM
Stempoint Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Stempoint Capital held 116 positions worth $581M, up 11% from $522M the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Stempoint Capital withdrew a net $54.7M in Q2 2026, closing 32 positions and reducing 30 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $28.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Stempoint Capital opened a new position in First Tracks Biotherapeutics worth $12.5M.
- Stempoint Capital's largest Q2 2026 buy was First Tracks Biotherapeutics: 622,723 shares worth $12.5M.
- Stempoint Capital added most to Tango Therapeutics in Q2 2026, an estimated $25.3M increase.
- Stempoint Capital's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $38.5M.
- Stempoint Capital fully exited Syndax Pharmaceuticals in Q2 2026, selling an estimated $28.4M.
- Stempoint Capital's ten largest holdings make up 41% of its $581M portfolio in Q2 2026.
- Stempoint Capital opened 34 new positions and closed 32 in Q2 2026.
- Stempoint Capital's portfolio value rose 11% quarter-over-quarter to $581M.
Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.